Abstract
Tumor-suppressor genes (TSGs) have been classically defined as genes whose loss of function in tumor cells contributes to the formation and/or maintenance of the tumor phenotype. TSGs containing nonsense mutations may not be expressed because of nonsense-mediated RNA decay (NMD). We combined inhibition of the NMD process, which clears transcripts that contain nonsense mutations, with the application of high-density single-nucleotide polymorphism arrays analysis to discriminate allelic content in order to identify candidate TSGs in five breast cancer cell lines. We identified ARID1A as a target of NMD in the T47D breast cancer cell line, likely as a consequence of a mutation in exon-9, which introduces a premature stop codon at position Q944. ARID1A encodes a human homolog of yeast SWI1, which is an integral member of the hSWI/SNF complex, an ATP-dependent, chromatin-remodeling, multiple-subunit enzyme. Although we did not find any somatic mutations in 11 breast tumors, which show DNA copy-number loss at the 1p36 locus adjacent to ARID1A, we show that low ARID1A RNA or nuclear protein expression is associated with more aggressive breast cancer phenotypes, such as high tumor grade, in two independent cohorts of over 200 human breast cancer cases each. We also found that low ARID1A nuclear expression becomes more prevalent during the later stages of breast tumor progression. Finally, we found that ARID1A re-expression in the T47D cell line results in significant inhibition of colony formation in soft agar. These results suggest that ARID1A may be a candidate TSG in breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adler HT, Chinery R, Wu DY, Kussick SJ, Payne JM, Fornace Jr AJ et al. (1999). Leukemic HRX fusion proteins inhibit GADD34-induced apoptosis and associate with the GADD34 and hSNF5/INI1 proteins. Mol Cell Biol 19: 7050–7060.
Belandia B, Orford RL, Hurst HC, Parker MG . (2002). Targeting of SWI/SNF chromatin remodelling complexes to estrogen-responsive genes. EMBO J 21: 4094–4103.
Berx G, van Roy F . (2009). Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol 1: a003129.
Biegel JA, Pollack IF . (2004). Molecular analysis of pediatric brain tumors. Curr Oncol Rep 6: 445–452.
Campeau PM, Foulkes WD, Tischkowitz MD . (2008). Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet 124: 31–42.
Carlson M, Laurent BC . (1994). The SNF/SWI family of global transcriptional activators. Curr Opin Cell Biol 6: 396–402.
Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG et al. (2005). Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 33: e175.
Dallas PB, Cheney IW, Liao DW, Bowrin V, Byam W, Pacchione S et al. (1998). p300/CREB binding protein-related protein p270 is a component of mammalian SWI/SNF complexes. Mol Cell Biol 18: 3596–3603.
Dallas PB, Pacchione S, Wilsker D, Bowrin V, Kobayashi R, Moran E . (2000). The human SWI–SNF complex protein p270 is an ARID family member with non-sequence-specific DNA binding activity. Mol Cell Biol 20: 3137–3146.
Dworkin AM, Huang TH, Toland AE . (2009). Epigenetic alterations in the breast: implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol 19: 165–171.
Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, Cole C et al. (2010). COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 38: D652–D657.
Grand F, Kulkarni S, Chase A, Goldman JM, Gordon M, Cross NC . (1999). Frequent deletion of hSNF5/INI1, a component of the SWI/SNF complex, in chronic myeloid leukemia. Cancer Res 59: 3870–3874.
Hassan S, Baccarelli A, Salvucci O, Basik M . (2008). Plasma stromal cell-derived factor-1: host derived marker predictive of distant metastasis in breast cancer. Clin Cancer Res 14: 446–454.
Hassan S, Ferrario C, Saragovi U, Quenneville L, Gaboury L, Baccarelli A et al. (2009). The influence of tumor-host interactions in the stromal cell-derived factor-1/CXCR4 ligand/receptor axis in determining metastatic risk in breast cancer. Am J Pathol 175: 66–73.
Hirschhorn JN, Bortvin AL, Ricupero-Hovasse SL, Winston F . (1995). A new class of histone H2A mutations in Saccharomyces cerevisiae causes specific transcriptional defects in vivo. Mol Cell Biol 15: 1999–2009.
Hosein AN, Wu M, Arcand SL, Lavallee S, Hebert J, Tonin PN et al. (2010). Breast carcinoma-associated fibroblasts rarely contain p53 mutations or chromosomal aberrations. Cancer Res 70: 5770–5777.
Huang J, Zhao YL, Li Y, Fletcher JA, Xiao S . (2007). Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosomes Cancer 46: 745–750.
Huusko P, Ponciano-Jackson D, Wolf M, Kiefer JA, Azorsa DO, Tuzmen S et al. (2004). Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet 36: 979–983.
Jones S, Wang TL, Shih Ie M, Mao TL, Nakayama K, Roden R et al. (2010). Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330: 228–231.
Kennison JA . (1995). The Polycomb and trithorax group proteins of Drosophila: trans-regulators of homeotic gene function. Annu Rev Genet 29: 289–303.
Li XS, Trojer P, Matsumura T, Treisman JE, Tanese N . (2010). Mammalian SWI/SNF—a subunit BAF250/ARID1 is an E3 ubiquitin ligase that targets histone H2B. Mol Cell Biol 30: 1673–1688.
Medina PP, Sanchez-Cespedes M . (2008). Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer. Epigenetics 3: 64–68.
Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A et al. (2005). An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102: 13550–13555.
Nagl Jr NG, Patsialou A, Haines DS, Dallas PB, Beck Jr GR, Moran E . (2005). The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest. Cancer Res 65: 9236–9244.
Nagl Jr NG, Wang X, Patsialou A, Van Scoy M, Moran E . (2007). Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell-cycle control. EMBO J 26: 752–763.
Nagl Jr NG, Zweitzig DR, Thimmapaya B, Beck Jr GR, Moran E . (2006). The c-myc gene is a direct target of mammalian SWI/SNF-related complexes during differentiation-associated cell cycle arrest. Cancer Res 66: 1289–1293.
Noensie EN, Dietz HC . (2001). A strategy for disease gene identification through nonsense-mediated mRNA decay inhibition. Nat Biotechnol 19: 434–439.
Orlando FA, Brown KD . (2009). Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis. Ann Surg Oncol 16: 2270–2279.
Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T et al. (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160–1167.
Patsialou A, Wilsker D, Moran E . (2005). DNA-binding properties of ARID family proteins. Nucleic Acids Res 33: 66–80.
Presneau N, Manderson EN, Tonin PN . (2003). The quest for a tumor suppressor gene phenotype. Curr Mol Med 3: 605–629.
Roberts CW, Biegel JA . (2009). The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biol Ther 8: 412–416.
Rodriguez-Nieto S, Sanchez-Cespedes M . (2009). BRG1 and LKB1: tales of two tumor suppressor genes on chromosome 19p and lung cancer. Carcinogenesis 30: 547–554.
Rozenblatt-Rosen O, Rozovskaia T, Burakov D, Sedkov Y, Tillib S, Blechman J et al. (1998). The C-terminal SET domains of ALL-1 and TRITHORAX interact with the INI1 and SNR1 proteins, components of the SWI/SNF complex. Proc Natl Acad Sci USA 95: 4152–4157.
Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science 314: 268–274.
Staden R, Beal KF, Bonfield JK . (2000). The Staden package, 1998. Methods Mol Biol 132: 115–130.
Strumane K, Berx G, Van Roy F . (2004). Cadherins in cancer. Handb Exp Pharmacol 165: 69–103.
Sudarsanam P, Cao Y, Wu L, Laurent BC, Winston F . (1999). The nucleosome remodeling complex, Snf/Swi, is required for the maintenance of transcription in vivo and is partially redundant with the histone acetyltransferase, Gcn5. EMBO J 18: 3101–3106.
Sudarsanam P, Iyer VR, Brown PO, Winston F . (2000). Whole-genome expression analysis of snf/swi mutants of Saccharomyces cerevisiae. Proc Natl Acad Sci USA 97: 3364–3369.
Takeuchi T, Chen BK, Qiu Y, Sonobe H, Ohtsuki Y . (1997). Molecular cloning and expression of a novel human cDNA containing CAG repeats. Gene 204: 71–77.
Takeuchi T, Furihata M, Heng HH, Sonobe H, Ohtsuki Y . (1998). Chromosomal mapping and expression of the human B120 gene. Gene 213: 189–193.
Vallone D, Battista S, Pierantoni GM, Fedele M, Casalino L, Santoro M et al. (1997). Neoplastic transformation of rat thyroid cells requires the junB and fra-1 gene induction which is dependent on the HMGI-C gene product. EMBO J 16: 5310–5321.
Van Rechem C, Boulay G, Leprince D . (2009). HIC1 interacts with a specific subunit of SWI/SNF complexes, ARID1A/BAF250A. Biochem Biophys Res Commun 385: 586–590.
Vogelstein B, Kinzler KW . (2004). Cancer genes and the pathways they control. Nat Med 10: 789–799.
Wang X, Nagl NG, Wilsker D, Van Scoy M, Pacchione S, Yaciuk P et al. (2004). Two related ARID family proteins are alternative subunits of human SWI/SNF complexes. Biochem J 383: 319–325.
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T et al. (2010). ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363: 1532–1543.
Wilsker D, Patsialou A, Zumbrun SD, Kim S, Chen Y, Dallas PB et al. (2004). The DNA-binding properties of the ARID-containing subunits of yeast and mammalian SWI/SNF complexes. Nucleic Acids Res 32: 1345–1353.
Winston F, Carlson M . (1992). Yeast SNF/SWI transcriptional activators and the SPT/SIN chromatin connection. Trends Genet 8: 387–391.
Yuge M, Nagai H, Uchida T, Murate T, Hayashi Y, Hotta T et al. (2000). HSNF5/INI1 gene mutations in lymphoid malignancy. Cancer Genet Cytogenet 122: 37–42.
Zhang B, Chambers KJ, Faller DV, Wang S . (2007). Reprogramming of the SWI/SNF complex for co-activation or co-repression in prohibitin-mediated estrogen receptor regulation. Oncogene 26: 7153–7157.
Acknowledgements
This study was supported by a grant from the Quebec Breast Cancer Foundation to Mark Basik and Patricia N Tonin. EP is supported by the McGill Integrated Cancer Research Training Program. The tumor bank was supported by the Fonds de Recherche en Santé du Quebec (FRSQ) through the Réseau de Cancer—Axe cancer du sein et de l’ovaire to MB.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Mamo, A., Cavallone, L., Tuzmen, S. et al. An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene 31, 2090–2100 (2012). https://doi.org/10.1038/onc.2011.386
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2011.386
Keywords
This article is cited by
-
ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes
Scientific Reports (2024)
-
Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy
Cancer Cell International (2023)
-
Identification of a novel GR-ARID1a-P53BP1 protein complex involved in DNA damage repair and cell cycle regulation
Oncogene (2022)
-
Loss of ARID1A expression is associated with systemic inflammation markers and has important prognostic significance in gastric cancer
Journal of Cancer Research and Clinical Oncology (2022)
-
Altered ARID1A expression in colorectal cancer
BMC Cancer (2020)